Locally Advanced/Metastatic/Recurrent ESCC

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Locally Advanced/Metastatic/Recurrent ESCC trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 3

NCT04415853

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

This is a randomized, controlled, multi-center, open trial, unresectable locally advanced or metastatic esophageal squamous cell carcinoma patients that failed…

China416 participantsStarted 2021-01-21

Treatment: Lerotinib, Irinotecan/Tegafur

All recent trials (6 shown)

Not Yet RecruitingPhase 3

NCT07417735

SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma

This study is a randomized, Controlled, Open-Label, Multicenter Phase Ⅲ Study of SYS6010 vs Investigator's Choice Single-Agent Chemotherapy in Locally Advanced/…

Location not specified436 participantsStarted 2026-03-18

Treatment: SYS6010, Investigator's Choice of Chemotherapy (Irinotecan hydrochloride，Paclitaxel，Docetaxel)

CompletedPhase 3

NCT03783442

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advance…

The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with a…

United States, Australia, Belgium649 participantsStarted 2018-12-11

Treatment:

Locally Advanced/Metastatic/Recurrent ESCC

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

All recent trials (6 shown)

SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advance…

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

All recent trials (6 shown)

SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advance…

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected…

A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )